Brineura 150 mg (Cerliponase Alfa SOLUTION) 150 MG

Brineura 150 mg is a solution containing cerliponase alfa, used for specific medical conditions. This medication is administered intracerebroventricularly and is manufactured by Biomarin International Limited in Ireland.

Strength

150 MG

Manufacturer / TM Owner

BIOMARIN INTERNATIONAL LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Brineura 150 mg is primarily used for the treatment of certain neurological disorders. The active ingredient, cerliponase alfa, is designed to address conditions that affect the brain. This medication is often prescribed for long-term management and requires specialized administration.

Side Effects

Common effects of Brineura 150 mg may include localized reactions at the injection site. Some individuals might experience mild to moderate discomfort or irritation. It is important to monitor for any unusual symptoms and consult a healthcare provider if concerns arise.

Precautions & Warnings

Brineura 150 mg should be handled with care, following the prescribed administration guidelines. Proper storage and handling are crucial to maintain the medication's efficacy. Always use this medication under the supervision of a healthcare professional.

Avoid Interactions

Brineura 150 mg may interact with other medications, particularly those that affect the central nervous system. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements may also affect the medication's performance.

Frequently Asked Questions

Brineura 150 mg is used for the treatment of specific neurological disorders. It contains cerliponase alfa, which targets conditions affecting the brain.

Brineura 150 mg is administered intracerebroventricularly, meaning it is delivered directly into the brain's ventricles.

Common side effects may include localized reactions at the injection site, such as discomfort or irritation.

Brineura 150 mg may interact with other medications, especially those affecting the central nervous system. Always consult a healthcare provider before combining medications.

Brineura 150 mg is manufactured by Biomarin International Limited in Ireland.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.